PLX - Protalix BioTherapeutics, Inc.

2.12
-0.030   -1.415%

Share volume: 722,028
Last Updated: 05-01-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.23%

PREVIOUS CLOSE
CHG
CHG%
$2.15
-0.03
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
29%
Profitability 32%
Dept financing 25%
Liquidity 27%
Performance 26%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-1.85%
1 Month
-1.40%
3 Months
-18.46%
6 Months
-11.30%
1 Year
-29.33%
2 Year
82.76%
Key data
Stock price
$2.12
P/E Ratio 
N/A
DAY RANGE
$2.12 - $2.16
EPS 
-$0.08
52 WEEK RANGE
$1.32 - $3.19
52 WEEK CHANGE
-$25.35
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
80.572 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-09-2025
BETA 
-0.50
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$510,359
AVERAGE 30 VOLUME 
$603,498
Company detail
CEO: Dror Bashan
Region: US
Website: protalix.com
Employees: 200
IPO year: 1998
Issue type: Common Stock
Market: NYSE American
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Protalix BioTherapeutics, Inc. focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials.

Recent news